Camila Simões

Assistant Professor

UAMS

Also affiliated: The University of Texas MD Anderson Cancer Center (2019); Universidade Federal de Pernambuco (2023); Yale University (2011); Mount Sinai Hospital (2020); Winthrop Rockefeller Foundation (2022–2025); The University of Texas Medical Branch at Galveston (2011–2019); University of Cincinnati Medical Center (2011); Icahn School of Medicine at Mount Sinai (2020–2024); Stetson University (2011)

Faculty Researcher

Pathology, College of Medicine

7 h-index 48 pubs 146 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Camila Simões studies the mechanisms of cancer and explores novel therapeutic strategies. Her research has investigated the potential of dietary methionine restriction to enhance the efficacy of immune checkpoint inhibitors in colorectal cancer models. She has also examined the use of oncolytic viruses, such as Morreton virus, as a treatment platform for liver cancers. Additionally, Simões has explored repurposing existing vaccines, like the MMR vaccine, for cancer immunotherapy.

Her work also extends to understanding genetic disorders, including identifying novel mutations in genes like YY1AP1 and LIS1 that are associated with severe medical conditions. Simões has also contributed to research on infectious diseases, specifically the dissemination of SARS-CoV-2. She is an Assistant Professor in Pathology at the University of Arkansas for Medical Sciences, with a scholarly record that includes 48 publications and an h-index of 7.

Metrics

h-index: 7
Publications: 48
Citations: 146

Selected Publications

Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

Cancer Research DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

Molecular Therapy Oncology 5 citations DOI OpenAlex
S3275 A Case of “Black Esophagus” Following Esophageal Candidiasis (2024)

The American Journal of Gastroenterology DOI OpenAlex
S5193 More Than Just a Variceal Bleed: Multiple Portal Hypertensive Gastric Polyps in a Case of Advanced Cirrhosis (2024)

The American Journal of Gastroenterology DOI OpenAlex
Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease (2024)

Modern Pathology 6 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 5 citations DOI OpenAlex
Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma (2024)

Cancer Research DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

Cancer Research DOI OpenAlex
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model (2023)

Cancers 31 citations DOI OpenAlex
S3266 A Comparison of Two Cases of Acute Graft versus Host Disease Following Liver Transplant (2022)

The American Journal of Gastroenterology 1 citation DOI OpenAlex
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)

Frontiers in Oncology 7 citations DOI OpenAlex
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers (2022)

Hepatology 14 citations DOI OpenAlex